RIGEL PHARMACEUTICALS, INC.

RIGL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-111.5M
Depreciation & Amortization $1.4M
Depreciation
Amortization
Stock-Based Compensation $13.4M
Net Cash from Operating Activities $-102.8M
Investing Activities
Capital Expenditures $141.0K
Business Acquisitions
Net Cash from Investing Activities
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities
Net Change in Cash
Free Cash Flow $-102.9M
← Newer Page 3 of 3 Older →